New research sheds light on how many hospitals are using artificial intelligence, what they’re using AI for, and what it means for patients and policymakers.
Federal Policy
RFK Jr. Wants to Change What Americans Eat. He’s Not The First.
The fight to improve Americans’ nutrition could get new momentum from Robert F. Kennedy Jr., but he will face practical and political limits to changing U.S. food supply if he’s confirmed to lead the Health and Human Services Department.
The Powerful Vaccine Committee RFK Jr. Could Soon Control
If the Senate confirms Robert F. Kennedy Jr. — a vaccine skeptic — to lead the Department of Health and Human Services, he would control an influential group of federal vaccine advisors.
Why Many Republicans Think Shrinking Medicaid Will Make it Better
Republicans have singled out Medicaid for possible cuts under the new administration and Congress. We explore why many conservatives think less Medicaid will mean better Medicaid.
Biden’s Medicaid Director Reflects on Lessons Learned and Worries for the Future
With Medicaid poised for potential cuts from Republicans in Washington, Dan Tsai reflects on what he’s learned running Medicaid for the Biden administration — and his hopes and concerns for the program’s future.
What Could RFK Jr. Do As Head of HHS? We Asked Someone Who’s Done the Job
Former HHS Secretary Kathleen Sebelius shares what the country’s top health official can and can’t do, and what she wants senators to know ahead of RFK’s confirmation hearings.
Health Policy on the Ballot
Learn more about where President-elect Donald Trump stands on critical health policy issues.
What the Election Could Mean for Obamacare
One of the nation’s leading experts on the Affordable Care Act breaks down its track record the stakes the historic law faces in the lead-up to the election.
3 Health Care Decisions Awaiting the Next President
The next U.S. president will have to make consequential choices about the Affordable Care Act, prescription drug prices and abortion.
Race to the Bottom: Where’s the Cavalry?
Some of the most powerful new medicines pose a host of challenges for drug companies trying to copy and sell similar versions on the cheap. Can those companies find a sustainable path forward, or will patients get left stuck paying exorbitant prices?
